Advertisement

Supportive Care in Cancer

, Volume 21, Issue 6, pp 1665–1675 | Cite as

The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients

  • Angela Ihbe-HeffingerEmail author
  • B. Paessens
  • K. Berger
  • M. Shlaen
  • R. Bernard
  • C. von Schilling
  • C. Peschel
Original Article

Abstract

Purpose

To evaluate frequency and severity of adverse drug reactions (ADRs) and its economic consequences after standard dose (immuno-)chemotherapy (CT) of non-small-cell lung cancer (NSCLC).

Patients and methods

Subanalysis of a prospective, multicentre, longitudinal, observational cohort study; data were collected from patient interviews and pre-planned chart reviews. Costs were aggregated per CT line and presented from provider perspective.

Results

A total of 120 consecutive NSCLC patients (mean age, 63.0 ± 8.4 (SD) years; men, 64.2 %; ECOG (Eastern Cooperative Oncology Group) performance status <2, 84.3 %; tumour stage III/IV, 85 %; history of comorbidity, 93.3 %) receiving 130 CT lines were evaluated. 80 % of CT lines were associated with grade 3 or 4 ADRs, 22.3 % developed potential life-threatening complications, 77.7 % were associated with at least one hospital stay (inpatient, 63.9 %; outpatient/day clinic 39.2 %, ICU 6.9 %), with a mean cumulative number of 12.8 (±14.0 SD) hospital days. Mean (median) toxicity management costs per CT line (TMC-TL) amounted to €3,366 (€1,406) and were found to be higher for first-line compared to second-line treatment: €3,677 (€1,599) vs. €2,475 (€518). TMC-TL were particularly high in CT lines with ICU care €12,207 (€9,960). Eight out of 11 ICU stays were associated with grade 3 or 4 infections. Nine CT lines with ICU care accounted for 25 % of total expenses (€109,861 out of €437,580).

Conclusions

In first-line NSCLC treatment, in particular, CT toxicity management is expensive. Asymmetric cost distribution seems to be triggered by infection associated ICU care. Its avoidance should reduce patients' clinical burden and have considerable economic implications. Nevertheless, comparative observational studies have to confirm estimated savings.

Keywords

Non-small-cell lung carcinoma Cancer chemotherapy Side effects Treatment costs Medical care costs 

Notes

Acknowledgments

We thank Volker Claus (PhD, BBA) for assistance in table and figure preparation (Health Economics & Outcomes Research, IMS HEALTH GmbH, München, Germany) and the study centres for participation. Subanalysis of the investigator sponsored study [23] and editorial assistance was supported by the Lilly Deutschland GmbH, Bad Homburg, Germany. The study sponsor was not involved in the study design, data collection, in the analysis and interpretation of data, in the writing of the manuscript and in the decision to submit the manuscript for publication.

Conflict of interests

Angela Ihbe-Heffinger: Research grants (Lilly, Amgen, Germany), lecturing fees (Amgen, Germany); all other authors declared no conflict of interest.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 127:2893–2917CrossRefGoogle Scholar
  2. 2.
    Travis WD, Travis LB, Devesa SS (1995) Lung cancer. Cancer 75:191–202PubMedCrossRefGoogle Scholar
  3. 3.
    Non-small cell lung cancer treatment (pdq®): http://wwwcancergov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional, National Cancer Institute at the National Institutes of Health, 2011
  4. 4.
    Azzoli CG, Baker S, Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2009) American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: published ahead of print on November 23, 2009 as 2010.1200/JCO.2009.2023.5622Google Scholar
  5. 5.
    Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831PubMedCrossRefGoogle Scholar
  6. 6.
    Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, Gaspar LE, Pass HI, Spigel DR, Strawn JR, Ung YC, Shepherd FA (2007) Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506–5518PubMedCrossRefGoogle Scholar
  7. 7.
    Felip E, Gridelli C, Baas P, Rosell R, Stahel R (2011) Metastatic non-small-cell lung cancer: Consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol 22:1507–1519PubMedCrossRefGoogle Scholar
  8. 8.
    Rajeswaran A, Trojan A, Burnand B, Giannelli M (2008) Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 59:1–11PubMedCrossRefGoogle Scholar
  9. 9.
    D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936PubMedCrossRefGoogle Scholar
  10. 10.
    Cella DF, Patel JD (2008) Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Clin Lung Cancer 9:206–212PubMedCrossRefGoogle Scholar
  11. 11.
    Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84PubMedCrossRefGoogle Scholar
  12. 12.
    Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP (2009) Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 15:669–682PubMedGoogle Scholar
  13. 13.
    Ihbe-Heffinger A, Paessens BJ, von Schilling C, Shlaen M, Gottschalk N, Berger K, Bernard R, Kiechle M, Peschel C, Jacobs VR (2011) Management of febrile neutropenia—a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer. Onkologie 34:241–246PubMedCrossRefGoogle Scholar
  14. 14.
    Mayordomo JI, Lopez A, Vinolas N, Castellanos J, Pernas S, Domingo Alonso J, Frau A, Layola M, Antonio Gasquet J, Sanchez J (2009) Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 25:2533–2542PubMedCrossRefGoogle Scholar
  15. 15.
    Banz K, Bischoff H, Brunner M, Chouaid C, de Castro Carpeno J, de Marinis F, Grossi F, Vergnenegre A, Walzer S (2011) Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer 74:529–534PubMedCrossRefGoogle Scholar
  16. 16.
    Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S (2004) Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43:101–112PubMedCrossRefGoogle Scholar
  17. 17.
    Bischoff HG, Heigener DF, Walzer S, Nuijten M (2010) Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 69(Suppl 1):S18–S23PubMedCrossRefGoogle Scholar
  18. 18.
    Chouaid C, Atsou K, Hejblum G, Vergnenegre A (2009) Economics of treatments for non-small cell lung cancer. PharmacoEconomics 27:113–125PubMedCrossRefGoogle Scholar
  19. 19.
    Neymark N, Lianes P, Smit EF, van Meerbeeck JP (2005) Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. PharmacoEconomics 23:1155–1166PubMedCrossRefGoogle Scholar
  20. 20.
    Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, Shepherd FA, Leighl NB (2011) An economic analysis of the interest trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol 22:1805–1811PubMedCrossRefGoogle Scholar
  21. 21.
    Weissflog D, Matthys H, Hasse J, Virchow JC Jr (2001) Epidemiology and costs of lung cancer in Germany. Pneumologie 55:333–338PubMedCrossRefGoogle Scholar
  22. 22.
    Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thodtmann J, Lordick F (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526–536PubMedCrossRefGoogle Scholar
  23. 23.
    Paessens BJ, von Schilling C, Berger K, Shlaen M, Muller-Thomas C, Bernard R, Peschel C, Ihbe-Heffinger A (2011) Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 22:2310–2319PubMedCrossRefGoogle Scholar
  24. 24.
    Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the national cancer institute common terminology criteria for adverse events: results of a questionnaire-based study. Lancet Oncol 7:903–909PubMedCrossRefGoogle Scholar
  25. 25.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268PubMedCrossRefGoogle Scholar
  26. 26.
    The Uppsala Monitoring Centre: The use of the WHO–UMC system for standardised case causality assessment: http://wwwwho-umcorg/graphics/4409.pdf, 2007, 2009
  27. 27.
    Comella P, Panza N, Manzione L, De Cataldis G, Cioffi R, Maiorino L, Lorusso V, Lamberti A, Micillo E, Natale M, Bilancia D, Nicolella G, Di Nota A, Mancarella S, Frasci G, Comella G (2000) Interim analysis of a phase III trial comparing cisplatin, gemcitabine, and vinorelbine vs. either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small-cell lung cancer. A Southern Italy Cooperative Oncology Group study. Clin Lung Cancer 1:202–207, discussion 208PubMedCrossRefGoogle Scholar
  28. 28.
    Comella P, Filippelli G, De Cataldis G, Massidda B, Frasci G, Maiorino L, Putzu C, Mancarella S, Palmeri S, Cioffi R, Roselli M, Buzzi F, Milia V, Gambardella A, Natale D, Bianco M, Ghiani M, Masullo P (2007) Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a Phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101). Ann Oncol 18:324–330PubMedCrossRefGoogle Scholar
  29. 29.
    Dedes KJ, Szucs TD, Bodis S, Joerger M, Lowy A, Russi EW, Steinert HC, Weder W, Stahel RA (2004) Management and costs of treating lung cancer patients in a university hospital. PharmacoEconomics 22:435–444PubMedCrossRefGoogle Scholar
  30. 30.
    Vergnenegre A, Corre R, Berard H, Paillotin D, Dujon C, Robinet G, Crequit J, Bota S, Thomas P, Chouaid C (2011) Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. J Thorac Oncol 6:161–168PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Angela Ihbe-Heffinger
    • 1
    • 2
    Email author
  • B. Paessens
    • 1
  • K. Berger
    • 3
    • 4
  • M. Shlaen
    • 4
  • R. Bernard
    • 1
  • C. von Schilling
    • 5
    • 6
  • C. Peschel
    • 5
  1. 1.Hospital Pharmacy Department, Klinikum rechts der IsarTechnische Universität MünchenMünchenGermany
  2. 2.Department of Gynaecology, Klinikum rechts der IsarTechnische Universität MünchenMunichGermany
  3. 3.Department of Transfusion Medicine and HaemostaseologyKlinikum der Universität MünchenMunichGermany
  4. 4.Health Economics & Outcomes ResearchIMS HEALTH GmbHMunichGermany
  5. 5.Third Medical Department, Klinikum rechts der IsarTechnische Universität MünchenMunichGermany
  6. 6.Department of Internal Medicine IIIKlinikum FreisingFreisingGermany

Personalised recommendations